Editing Methylphenidate (section)

===Social anxiety===
Methylphenidate has been reported to be effective in the treatment of [[social anxiety disorder]] in people who are [[comorbidity|comorbid]] for both this condition and [[attention deficit hyperactivity disorder]] (ADHD) in small preliminary [[clinical study|clinical studies]] and [[case report]]s.<ref name="VillasBoasChierritoFernandez-Llimos2019">{{cite journal | vauthors = Villas-Boas CB, Chierrito D, Fernandez-Llimos F, Tonin FS, Sanches AC | title = Pharmacological treatment of attention-deficit hyperactivity disorder comorbid with an anxiety disorder: a systematic review | journal = Int Clin Psychopharmacol | volume = 34 | issue = 2 | pages = 57–64 | date = March 2019 | pmid = 30422834 | doi = 10.1097/YIC.0000000000000243 | url = | quote = In a retrospective analysis of a case series, the monotherapy with extendedrelease methylphenidate was seen to be effective in reducing ADHD and social AD symptoms evaluated by the Adult ADHD Self-Report Scale (ASRS) and Liebowitz Social Anxiety Scale (LSAS) (Koyuncu et al., 2017).}}</ref><ref name="KoyuncuİnceErtekin2019">{{cite journal | vauthors = Koyuncu A, İnce E, Ertekin E, Tükel R | title = Comorbidity in social anxiety disorder: diagnostic and therapeutic challenges | journal = Drugs Context | volume = 8 | issue = | pages = 212573 | date = 2019 | pmid = 30988687 | pmc = 6448478 | doi = 10.7573/dic.212573 | url = | quote = Attention-deficit/hyperactivity disorder (ADHD), another childhood disorder that extends over adulthood, is an overlooked condition that has high rates of comorbidity with SAD.31 Only recently increasing evidence suggests that the relationship between the two disorders is closer than was thought before. Several studies found high rates (up to 60–70%) of childhood ADHD comorbidity, especially predominantly inattentive type, in adults with SAD.67,157,158 In addition, follow-up studies showed that the lifetime prevalence of SAD among ADHD patients is higher compared to healthy controls.159 Treatment studies investigating patients with SAD plus ADHD comorbidity found that ADHD medications such as methylphenidate or atomoxetine could effectively improve symptoms of both disorders at the same time.160–163 According to a developmental hypothesis, SAD may be etiologically linked to ADHD in a subgroup of patients, and thus SAD may develop secondary to ADHD.31}}</ref><ref name="PelissoloAbouKassmDelhay2019">{{cite journal | vauthors = Pelissolo A, Abou Kassm S, Delhay L | title = Therapeutic strategies for social anxiety disorder: where are we now? | journal = Expert Rev Neurother | volume = 19 | issue = 12 | pages = 1179–1189 | date = December 2019 | pmid = 31502896 | doi = 10.1080/14737175.2019.1666713 | url = | quote = Recently, clinical studies have found high rates of Attention-deficit/hyperactivity disorder (ADHD) in SAD children (up to 60-%), but also in adults [98]. Koyuncu et al. proposed a “developmental hypothesis”, suggesting that SAD may be etiologically linked to ADHD in a subgroup of patients. The impact of this association on response to treatment still needs investigations, but preliminary studies showed that atomoxetine and methylphenidate can be effective in treating both ADHD and comorbid SAD [99,100].}}</ref><ref name="GolubchikSeverWeizman2014">{{cite journal | vauthors = Golubchik P, Sever J, Weizman A | title = Methylphenidate treatment in children with attention deficit hyperactivity disorder and comorbid social phobia | journal = Int Clin Psychopharmacol | volume = 29 | issue = 4 | pages = 212–215 | date = July 2014 | pmid = 24448460 | pmc = 4047304 | doi = 10.1097/YIC.0000000000000029 | url = }}</ref><ref name="KoyuncuÇelebiErtekin2015">{{cite journal | vauthors = Koyuncu A, Çelebi F, Ertekin E, Kahn DA | title = Extended-release Methylphenidate Treatment and Outcomes in Comorbid Social Anxiety Disorder and Attention-deficit/Hyperactivity Disorder: 2 Case Reports | journal = J Psychiatr Pract | volume = 21 | issue = 3 | pages = 225–231 | date = May 2015 | pmid = 25955266 | doi = 10.1097/PRA.0000000000000070 | url = }}</ref><ref name="KoyuncuCelebiErtekin2017">{{cite journal | vauthors = Koyuncu A, Çelebi F, Ertekin E, Kök BE, Tükel R | title = Extended-release methylphenidate monotherapy in patients with comorbid social anxiety disorder and adult attention-deficit/hyperactivity disorder: retrospective case series | journal = Ther Adv Psychopharmacol | volume = 7 | issue = 11 | pages = 241–247 | date = November 2017 | pmid = 29090087 | pmc = 5638159 | doi = 10.1177/2045125317714193 | url = }}</ref>